March 1, 2005 Biotech rallied into the closing bell today. It was a small bounceback from yesterday’s tumultuous sell-off, caused by the shocking recall of Tysabri. After trading lower through much of the day, the Centient Biotech 200 gained 9 points to 3214.24, a rise of .28%. That was slightly behind a .41% gain in the NYSE Composite and a .95% rise in Nasdaq. We look at the rally attempts in Biogen Idec and Elan, the FDA approval for Biovail and Depomed, the Phase II trial for NeuroVax from Immune Response, good Q4 numbers from Sanofi-Aventis, a downgrade for Third Wave Technologies, and a disappointing report from Discovery Partners International.
